{"id":"NCT03112603","sponsor":"Incyte Corporation","briefTitle":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","officialTitle":"A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH3)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-29","primaryCompletion":"2020-05-08","completion":"2022-12-15","firstPosted":"2017-04-13","resultsPosted":"2022-04-15","lastUpdate":"2025-08-12"},"enrollment":330,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Graft-versus-host Disease (GVHD)"],"interventions":[{"type":"DRUG","name":"Ruxolitinib","otherNames":["Jakafi, INCB018424"]},{"type":"DRUG","name":"Extracorporeal photopheresis (ECP)","otherNames":[]},{"type":"DRUG","name":"Low-dose methotrexate (MTX)","otherNames":[]},{"type":"DRUG","name":"Mycophenolate mofetil (MMF)","otherNames":[]},{"type":"DRUG","name":"mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)","otherNames":[]},{"type":"DRUG","name":"Infliximab","otherNames":[]},{"type":"DRUG","name":"Rituximab","otherNames":[]},{"type":"DRUG","name":"Pentostatin","otherNames":[]},{"type":"DRUG","name":"Imatinib","otherNames":[]},{"type":"DRUG","name":"Ibrutinib","otherNames":[]}],"arms":[{"label":"Ruxolitinib","type":"EXPERIMENTAL"},{"label":"Best Available Therapy","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).","primaryOutcome":{"measure":"Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit","timeFrame":"Cycle 7 Day 1 (each cycle was comprised of 4 weeks)","effectByArm":[{"arm":"Ruxolitinib","deltaMin":49.7,"sd":null},{"arm":"Best Available Therapy","deltaMin":25.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":191,"countries":["United States","Australia","Austria","Belgium","Bulgaria","Canada","Czechia","Denmark","France","Germany","Greece","Hungary","India","Israel","Italy","Japan","Jordan","Netherlands","Norway","Poland","Portugal","Puerto Rico","Romania","Russia","Saudi Arabia","South Korea","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["40561385","40472328","35363318","34260836","29316837"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":86,"n":165},"commonTop":["Anaemia","Hypertension","Pyrexia","Diarrhoea","Cough"]}}